

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3896309

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NOVARTIS AG	05/23/2016
RECEIVING PARTY DATA	
Name:	GLAXOSMITHKLINE BIOLOGICALS SA
Street Address:	RUE DE L'INSTITUT 89
City:	RIXENSART
State/Country:	BELGIUM
Postal Code:	1330
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	12225501
Application Number:	12287225
CORRESPONDENCE DATA	
Fax Number:	(415)268-7522
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	415-268-6846
Email:	mstout@mofo.com
Correspondent Name:	OTIS LITTLEFIELD
Address Line 1:	MORRISON & FOERSTER LLP
Address Line 2:	425 MARKET STREET
Address Line 4:	SAN FRANCISCO, CALIFORNIA 94105-2482
ATTORNEY DOCKET NUMBER:	303822006900 303822006920
NAME OF SUBMITTER:	OTIS LITTLEFIELD
SIGNATURE:	/Otis Littlefield/
DATE SIGNED:	05/31/2016
Total Attachments: 2	
source=Assignment_to_GlaxoSmithKline_Biologicals_SA_30382-2006900#page1.tif	
source=Assignment_to_GlaxoSmithKline_Biologicals_SA_30382-2006900#page2.tif	

CONFIRMATORY ASSIGNMENT

WE, **NOVARTIS AG** a company limited by shares duly incorporated in Switzerland and whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland do hereby declare that we are the sole owner of the following patents/ patent applications entitled "REGIMENS FOR IMMUNISATION WITH MENINGOCOCCAL CONJUGATES".


Country	Application Date	Application Number	Grant Date	Patent Number
AU	02-Sep-13	2013222031		
AU	12-Jun-15	2015203146		
AT	22-Mar-07	07753720 7	25-Apr-12	EP2004225
BE	22-Mar-07	07753720 7	25-Apr-12	EP2004225
CA	22-Mar-07	2646993	26-Jan-16	2646993
CZ	22-Mar-07	07753720 7	25-Apr-12	EP2004225
DK	22-Mar-07	07753720 7	25-Apr-12	EP2004225
EP	28-Feb-11	11156356 5		
EP	22-Mar-07	07753720 7	25-Apr-12	EP2004225
FI	22-Mar-07	07753720 7	25-Apr-12	EP2004225
FR	22-Mar-07	07753720 7	25-Apr-12	EP2004225
GB	22-Mar-07	07753720 7	25-Apr-12	EP2004225
DE	22-Mar-07	07753720 7	25-Apr-12	602007022267 2
GR	22-Mar-07	07753720 7	25-Apr-12	EP2004225
HU	22-Mar-07	07753720 7	25-Apr-12	EP2004225
IE	22-Mar-07	07753720 7	25-Apr-12	EP2004225
IT	22-Mar-07	502012902069241	25-Apr-12	EP2004225
LU	22-Mar-07	07753720 7	25-Apr-12	EP2004225
NL	22-Mar-07	07753720 7	25-Apr-12	EP2004225
NZ	22-Mar-07	572054	02-Apr-12	572054
PL	22-Mar-07	07753720 7	25-Apr-12	EP2004225
PT	22-Mar-07	07753720 7	25-Apr-12	EP2004225
CH	22-Mar-07	07753720 7	25-Apr-12	EP2004225
SI	22-Mar-07	07753720 7	25-Apr-12	EP2004225
SK	22-Mar-07	07753720 7	25-Apr-12	EP2004225
ES	22-Mar-07	07753720 7	25-Apr-12	EP2004225
SE	22-Mar-07	07753720 7	25-Apr-12	EP2004225
TR	22-Mar-07	2012/08459	25-Apr-12	EP2004225
US	22-Mar-07	12/225501		
US	06-Oct-08	12/287225		

And in accordance with the Intellectual Property Assignment Agreement dated 2 March 2015 between **NOVARTIS AG** and **GLAXOSMITHKLINE BIOLOGICALS SA**, for good and valuable consideration, the receipt of which is hereby acknowledged, we **NOVARTIS AG** have assigned the entire right, title and interest and from which priority may be claimed from one or more applications, or any division, continuation and continuation-in-part of said application to in and to said patent application and all countries in which this/ these application(s) are filed to **GLAXOSMITHKLINE BIOLOGICALS SA** of Rue de l'Institut 89, 1330 Rixensart, Belgium


VN51985

Dated this 23 day of May 2016

Signed for and on behalf of
NOVARTIS AG




Edward R. Ginnai
Authorized Signatory on behalf of
NOVARTIS AG



Lorraine B. Ling
Authorized Signatory on behalf of
NOVARTIS AG

Signed for and on behalf of
GLAXOSMITHKLINE BIOLOGICALS SA



Theodore R. Furman
Authorized Official on behalf of
GLAXOSMITHKLINE BIOLOGICALS SA